Abstract Permanent ductal closure involves anatomic remodeling, in which transforming growth factor (TGF)-b appears to play a role. Our objective was to evaluate the relationship, if any, between blood spot TGF-b on day 3 and day 7 of life and patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) infants. Prospective observational study involving ELBW infants (n = 968) in the National Institute of Child Health and Human Development Neonatal Research Network who had TGF-b measured on filter paper spot blood samples using a Luminex assay. Infants with a PDA (n = 493) were significantly more immature, had lower birth weights, and had higher rates of respiratory distress syndrome than those without PDA (n = 475). TGF-b on days 3 and 7 of life, respectively, were significantly lower among neonates with PDA (median 1,177 pg/ml [range 642- Cardiol (2013) 34:149-154 DOI 10.1007 significant difference persisted when death or PDA was considered a composite outcome. TGF-b levels were not significantly different among subgroups of infants with PDA who were not treated (n = 51) versus those who were treated medically (n = 283) or by surgical ligation (n = 159). TGF-b was not a significant predictor of death or PDA (day 3 odds ratio [OR] 0.99, 95 % confidence interval [CI] 0.83-1.17; day 7 OR 0.88, 95 % CI 0.74-1.04) on adjusted analyses. Our results suggest that blood spot TGF-b alone is unlikely to be a reliable biomarker of a clinically significant PDA or its responsiveness to treatment.
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Introduction
Patent ductus arteriosus (PDA) is a frequent occurrence in preterm infants, with reported rates of 40-55 % among those born at \29 weeks' gestation [8, 12] . The process of ductal closure occurs in two phases: (1) functional constriction soon after birth followed by anatomic permanent closure; and (2) neointimal cushion formation by migration of smooth muscle cells from the muscle media into the subendothelial space, which eventually occlude the ductal lumen [5] . Anatomic remodeling appears to be initiated by ductal wall hypoxia, although the precise mechanisms remain unclear. Studies on animal models suggest that transforming growth factor (TGF) contributes to the mechanisms of anatomic ductal closure [2, 10, 11, 15] . Our objective in the current exploratory analyses was to examine the relationship, if any, between blood spot TGF-b on days 3 and 7 of life and PDA in extremely low-birth weight (ELBW) infants.
Patients and Methods
Study Population
This is a secondary analyses of data collected from preterm infants who participated in the Inflammatory Cytokines and Neurodevelopmental Outcomes in Extremely Low Birth Weight Infants study of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) multicenter Neonatal Research Network (NRN) [3] . The study was approved by the Institutional Review Boards of all participating centers, and informed parental consent was obtained. Preterm infants with birth weights between 401 and 1,000 g, in whom TGF-b levels were obtained at least once on either day 3 and 7, were included.
Study Procedures
Clinically significant PDA was defined as clinical evidence of left-to-right PDA shunt, i.e., a continuous murmur, hyperdynamic precordium, bounding pulses, wide pulse pressure, congestive heart failure, increased pulmonary vascularity or cardiomegaly by chest radiograph, and/or increased oxygen requirement or echocardiographic evidence of left-to-right ductal shunting. Although not required by the NRN, all of the NRN centers confirmed clinical symptoms with echocardiography for the presence of PDA. Infants without PDA comprised the comparison control group. Whole-blood spots, dried on filter paper, were obtained on days 3 ± 1 and 7 ± 1 of life from indwelling arterial/venous lines or heel sticks, allowed to dry at room temperature, and stored at -20°C. TGF-b measurement was by xMAP (multiplex Luminex) assay (Luminex, Austin, TX) with reported intra and interassay coefficients of variation of 6.8 and 18 %, respectively, and constant TGF-b amounts during storage [9] .
Data Analysis
Statistical analyses (SAS version 9.1.3 [SAS, Cary, NC]) included Wilcoxon test for unadjusted comparisons of variables between two groups of infants with and without clinically significant PDA. For comparisons of TGF-b blood spot concentrations between subgroups of infants with PDA who were not treated and those who were treated medically or by surgical ligation, Kruskal-Wallis nonparametric tests were used. Logistic regression was used to determine the association between TGF-b and a PDA after adjusting for covariates. Statistical significance was set at a p \ 0.05.
Results
Demographic Characteristics
Among 1,067 extremely preterm infants who participated in the primary cytokines study of the NICHD multicenter NRN, 968 with a TGF-b sample at either time point (day 3 or day 7 of life) were included. Figure 1 depicts the study cohort and outcomes, and Table 1 shows that infants with PDA were significantly more premature, had lower mean birth weight, and had a higher incidence of respiratory distress syndrome (RDS) requiring surfactant (all p \ 0.0001).
TGF-b and PDA
Blood spot TGF-b concentrations on days 3 and 7 were significantly lower in the PDA group (n = 493) compared with the no-PDA group (n = 475), although this was with considerable overlap (p \ 0.01) ( Table 2) . When death and/or PDA, respectively, was used as a composite outcome, TGF-b levels at both time points were significantly lower in those who died or had a PDA than among survivors without PDA (day 3 = 1,182 (range 643-1,868) pg/ml vs. 1,370 (range 761-2,079) pg/ml [p \ 0.005] and day 7 = 1,382 (range 865-1,923) pg/ml vs. 1,749 (range 1,046-2,550) pg/ml [p \ 0.0001]). Among subgroups of surviving infants, the difference remained significant (p \ 0.0001) on day 7 but not on day 3. There were no significant differences in blood spot TGF-b levels at either time point between subgroups of infants with PDA who were not treated and those who were treated medically or by surgical ligation ( (Table 4) .
Discussion
TGF-b is a potent modulator of vascular smooth-muscle cell migration and is thought to play a role in ductal closure [2, 6] . TGF-b 1 is found in the wall of the fetal ductus and increases during postnatal closure [2, 11] . In full-term lambs, TGF-b protein and mRNA are present in low levels in late gestation with enhanced expression in the neointima and outer muscle media within 24 h of birth and a progressive increase during the next 10 days [11] . TGF-b has been shown to regulate increased ductus arteriosus endothelial glycoaminoglycan synthesis, which is associated with intimal proliferation [2] . In a fetal lamb model, intimal cushion formation was shown to be secondary to increased hyaluron synthesis, a TGF-b-dependent process [15] . Certain genetic conditions, such as Loeys Dietz syndrome, associated with mutations of the TGFBR2 gene may manifest in the neonatal period with clinical features, including PDA with or without ductal aneurysm [14] .
There has been only a single previous study exploring the relationship between TGF-b and PDA in preterm (\32 weeks) infants. Median bronchoalveolar lavage fluid concentrations of both vascular endothelial growth factor (VEGF) and TGF-b1 on day 3, respectively, were found to be significantly greater in the PDA group (n = 17) (3,319 vs. 1,514 [p = 0.02]; 18,692 vs. 13,057 [p = 0.03] ) compared with controls (n = 23) [13] . The investigators postulated that greater VEGF may be central to the acute injury phase, determining persistence of the PDA, whereas increased TGF-b1 may represent an attempted response to close the ductus. Early-onset sepsis 10 (2) 6 (1) 0.45
Small for gestation 40 (8) 97 (20) \0.0001
a p Values are from nonparametric Wilcoxon two-sample test (t approximation) for continuous variables and from Fisher's exact test for categorical variables b RDS is defined as clinical features of RDS within age 24 h. We also have data for oxygen requirement from 6 to 24 h, need for respiratory support to 24 h, and abnormal chest X-ray within 24 h. Incorporating these items brings RDS to 100 % in both groups Our exploratory analyses on a large cohort of preterm infants is the first attempt to uncover a possible correlation between blood TGF-b levels and PDA and calls for further focused investigation. The lack of demonstration of an independent association with clinically significant PDA is probably because blood TGF, although most easily accessible, may not reflect ductal-tissue concentrations or local function. The significantly lower blood TGF-b concentrations noted in the PDA group can probably be ascribed to the lower gestation and birth weight in this group. Previous data have showed a moderate positive correlation between TGF-b in bronchoalveolar lavage fluid and gestation and birth weight [4] .
Limitations
The limitations of our study are that TGF-b may be altered by factors such as maternal chorioamnionitis, bronchopulmonary dysplasia, and platelet count [1, 4, 7] . Our assay measured total TGF-b, not the subunits. We opted to evaluate blood spot TGF on days 3 and 7 of life, the period of anticipated anatomic ductal closure but we did not have data on the exact timing of diagnosis of PDA or its treatment. The definition of clinically significant PDA in our data set included echocardiographic findings of any leftto-right shunt across the PDA. We attempted to discriminate hemodynamically significant and nonsignificant PDA by comparing subgroups of infants with PDA who were not treated with those who were treated medically or by surgical ligation. We recognize, however, that we did not have stringent echocardiographic findings of left atrial enlargement or ductal size to support the diagnosis of hemodynamically significant PDA and that there are enormous practice variations in the decision to evaluate for and treat PDA.
Our results suggest that blood spot TGF-b alone is unlikely to be a reliable biomarker of clinically significant PDA. There remains an urgent need to identify objective biomarkers for the occurrence, severity, and responsiveness of PDA, which in turn could lead to a more rational approach to its management.
